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ABSTRACT
Hepatitis C virus (HCV) is a global epidemic that has been increasing for decades, afflicting
millions of people who inject drugs (PWID) and is a major cause of liver disease. With novel
direct-acting antivirals, treating the virus has become possible yet elimination remains out of
reach. Prior research has shown significant differences in disease progression between men
and women. These differences can lead to variation in incidence or what proportion of
infections progress to chronic infections. We develop a mathematical model that accounts for
potential differences between the sexes to evaluate the impacts on HCV transmission. We
find that susceptibility is the strongest predictor of prevalence over time, but spontaneous
clearance can lead to prevalence reductions, especially in women, when susceptibility is low.
Finally, we test three hypothetical populations and discover that applying treatment against a
natural bias in the population may prove more efficient than equal application.
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Introduction
Hepatitis C Virus (HCV) is a major cause of liver diseases and chronically affects as
many as 71 million people globally (WHO, 2017). The ongoing HCV epidemic primarily
concerns people who inject drugs (PWID) due to high prevalence in long-term users causing
new users to quickly acquire HCV (Aceijas and Rhodes, 2007; Amato et al., 2005; Chen and
Morgan, 2006; Degenhardt et al., 2017; Hagan et al., 2007; Larney et al., 2015; Page et al.,
2013; Shepard et al., 2005; Suryaprasad et al., 2014). While transmission routes are mostly
through susceptible individuals coming into direct contact with infectious blood, individuals
in this population engage in several risky behaviors such as sharing injection syringes or
“rinsing” their injections, which facilitates this contact (Evans et al., 2003; Gilchrist et al.,
2017; Hahn et al., 2002; Lapane et al., 1998; Larney et al., 2015; Morris et al., 2015; 2017;
2018; Murray et al., 2003; Platt et al., 2016; 2018; Turner et al., 2011). As a largely
asymptomatic infection, many infected individuals are unaware of their status and thus
unknowingly transmit the infection to their injection partners (Chen and Morgan, 2006).
Additionally, with no long-term immunity to the infection, even those who recover are
susceptible to new infections and can rapidly acquire HCV again (Chen and Morgan, 2006;
Grebely et al., 2012; Page et al., 2009). While the methods of treatment have improved over
the past decade it has done little to curb the epidemic, indicating that optimization of
interventions is a key area for future research.
In recent years, Direct-Acting Antiviral (DAA) treatments have reached high levels of
efficacy (over 95%) and researchers have begun to consider widespread treatment as a form
of prevention (Dahari et al., 2016; Hahn et al., 2002; Harris et al., 2015; Martin et al., 2011a;
2013a; Read et al., 2017; Zelenev et al., 2018). Under this plan, rather than focusing on

2

prevention with a vaccine, the principle is that large applications of treatment can reduce
HCV prevalence to the point where there is little risk of transmission (Bajis et al., 2017;
Martin et al., 2011b). While several models have shown that scaling up treatment application
can lead to significant decreases in prevalence and thus transmission in certain populations;
there has been little success in replicating these results on a global scale. (Grebely and Dore,
2014; Grebely et al., 2017; Larney et al., 2017; Martin et al., 2011a; Moreno et al., 2017;
Palmateer et al., 2014; Platt et al., 2016; Scott et al., 2016; Ward et al., 2018).
In order to eliminate HCV as a public health threat across the globe, it is not enough
to just consider upscaling treatment. A comprehensive intervention plan would not only
include increasing diagnosis and treatment, but also scaling up current harm reduction
programs such as syringe-service centers or opioid substitution therapy (WHO, 2017). Before
we can consider these more expansive plans though, there are several factors which have yet
to be explored. One such factor is the potential impact of sex on transmission or disease
progression. Investigations into other human diseases indicate that sex plays a significant role
in disease burden and treatment outcomes (Klein, 2000; Klein and Flanagan, 2016; Furman
et al., 2014). These differences are not only a result of biological factors but can be a result of
behavioral or social ones as well (Berg et al., 2004; Stockdale et al., 2007). Understanding
the impact of sex on HCV, as well as other factors, would allow for more efficient
interventions of the epidemic on a global scale.
It has been shown that several risk factors can lead to increased transmission and
result in a higher susceptibility to HCV within certain populations (Alter, 1997; Awofeso,
2010; Degenhardt et al., 2017; Hagan et al., 2007; Hahn et al., 2002). Some of this risk is
associated with societal barriers that may contribute to low levels of diagnosis or treatment,
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such as reduced access to care or associated stigmas with the virus (Awofeso, 2010; Puzhko
et al., 2017; Vickerman et al., 2012; Olsen et al., 2013). Other components of this increased
risk seem to be biological, such as genetic differences between sexes or populations (Cai et
al., 2014). Several of the factors associated with increased risk of acquiring infections have
been shown to be associated with sex as well (Esmaeili et al., 2017; 2018; Evans et al., 2003;
Iversen et al., 2010; 2015; Lidman et al., 2009; Page et al., 2013).
With HCV, another clear indicator of a biological difference between sexes is
spontaneous clearance. Individuals are defined to be in an acute stage of the infection for the
first 6 months after acquisition (Baden et al., 2014; Hajarizadeh et al., 2013). If the infection
persists after 6 months, it is considered a chronic HCV infection (Baden et al., 2014;
Hajarizadeh et al., 2013). Certain acutely infected individuals spontaneously recover from the
virus without intervention (Fedorchenko et al., 2010; Grebely et al., 2012; Grebely et al.,
2007; Micallef et al., 2006; Poustchi et al., 2011; Sarkar et al., 2013; Wang et al., 2007;
Yeung et al., 2007). Such events are identified by detecting the presence of HCV antibodies
in an individual without any detection of viral RNA. This process of spontaneous clearance
occurs in women at a much higher rate than men (Bakr et al., 2006; Berg et al., 2004; Corsi
et al., 2016; Fedorchenko et al., 2010; Grebely et al., 2007; Page et al., 2009; Wang et al.,
2007; Yamakawa et al., 1996). Modeling work on HCV often includes a spontaneous
clearance rate but leaves the rate flat across the entire population rather than different
depending on sex, this is primarily because most models do not differentiate between the two
sexes (Cousien et al., 2015; Fraser et al., 2018a; 2018b; Gountas et al., 2017; Li et al., 2015;
Martin et al., 2011a; 2011b; 2013a; 2013b; Vickerman et al., 2012). A higher recovery rate
without treatment could lead to lower overall prevalence within one part of the population.
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Together, these factors could contribute to a differential susceptibility between sexes which
might also impact treatment or transmission. In this paper, we develop a sex-structured
model of HCV transmission to investigate the impact sex has on prevalence and treatment of
the virus.
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Methods
Model Structure
We developed a system of ordinary differential equations to model HCV transmission in the
PWID population (Figure 1). The model is built upon the commonly used SIS model of
infection, where individuals move from a susceptible population, acquire infections, and
either die or recover and move back into the susceptible population. Our model includes one
class for Susceptible Individuals (S) but stratifies the infectious population into sub-classes:
Acute Infection (A), Chronic Infection (C), On Treatment (T), and Failed Treatment (F).
Individuals exit each of these states at a per capita rate equal to the mortality rate (𝜇𝜇1) plus
the injection cessation rate (𝜇𝜇2). As we are focused on the PWID population, individuals who
stop injecting are no longer assumed to be contributing to transmission within the population.
Individuals enter the susceptible population at a recruitment rate (𝜃𝜃) which is set to keep the
population constant at 100,000 individuals.
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Figure 1. Flow diagram showing the 5 classes for the male population and the paths that move between them. The female
population uses an identical flow diagram.

Using this model structure, two different base-line models were constructed. In the
null model, all individuals are grouped together in one of the five classes while the sexstructured model groups individuals into five classes for males and five for females, denoted
by the subscripts m and f respectively. While in the susceptible population, individuals
acquire new infections at a rate determined by the infection rate (β) and the proportion of
infectious individuals in the population. In the sex-structured model, the population is
assumed to be homogenously mixed, whereby the proportion of infectious individuals is the
total of all males and females in the infectious classes over the entire population size. The
classes which are assumed to contribute to the force of infection are acute, chronic, on
treatment, and failed treatment. Acutely infected individuals leave at a per capita rate
equivalent to assuming an average infection period of 6 months (1�𝜆𝜆). Individuals leaving the
acute state either spontaneously recover (with probability p) or progress to chronic infection
(with probability 1 - p). Chronically infected individuals remain in their class until they are
treated.
The null model is initialized with a susceptible population and a chronically infected
population resulting in an initial prevalence of 16% based on cohort data from the U-FindOut study. The sex-structured model has initial susceptible and chronically infected males
and females but has the same initial prevalence over both sexes. Since data on acute
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individuals is sparse, we assumed that there are no individuals in the acute class at the start of
the model to prevent overestimation of disease burden. The model is then evaluated for
several years and the final class populations are recorded.

Treatment Mechanics
We make a few assumptions about how treatment is distributed and utilized. In both
models, a yearly maximum number of treatments is assigned (ꞷ) to represent a financial or
logistical ceiling in the population. In the sex-structured model, these treatments are split
with each sex being given a proportional amount of treatments depending on what percent of
the total population they represent (i.e. if males make up 90% of the population, they receive
90% of the maximum treatments). At each time step, the number of chronically infected
individuals is compared to this maximum number of treatments per year to generate a
treatment proportion. If this treatment proportion is below our maximum treatment
proportion (mtp, the proportion of the population we realistically assume we can reach) we
treat all chronic individuals. If this treatment proportion is above our mtp then we assume we
can only treat up to the mtp (as in, we cannot treat individuals we cannot access). If the
proportion of chronic individuals is less than our mtp for the entire year, we end up with
excess treatments that were not used to treat anyone. At the end of each year in the model,
these unused treatments are added up and included into the maximum number of treatments
for the next year.
Individuals in the treated class are assumed to stay within the class for the average
duration of treatment which is 12 weeks (1�𝜂𝜂 ). Individuals who have been successfully
treated (proportion ε) re-enter the susceptible population, while individuals who failed
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treatment (proportion 1 - ε) enter the failed treatment population. Individuals who have failed
treatment once are assumed to not be treated again.

Sensitivity Analysis
To investigate the impact of population ratio, viral susceptibility, and spontaneous
clearance on the final prevalence of HCV we conducted a global sensitivity analysis. Using
Latin hypercube sampling (LHS) we generated 10,000 parameter sets, assuming a uniform
distribution for each of our 5 parameters. These parameters each had their own range,
corresponding with what was assumed to match real scenarios. The 5 parameters we sampled
were population ratio (0% male to 100% male populations), male viral susceptibility (0.20.8), female viral susceptibility (0.2-0.8), male spontaneous clearance (0.1-0.3), and female
spontaneous clearance (0.2-0.4). Each parameter set was input into the sex-structured model
and run for 30 years with no treatments applied and the final prevalence of HCV was
calculated as a proportion of the population. We then ran the same 10,000 sets through the
model again but over the 30 years applied a flat rate of treatment. We used local regression to
estimate trends between each parameter with respect to the final prevalence of HCV at 30
years as well as calculated the average relative impact (ARI) on final prevalence. To
calculate the ARI we used base values for each parameter drawn from the literature (Table
1). For the population ratio, we assumed a baseline population would match the global sex
ratio of roughly 1:1 (WHO, 2020). Then for every sample of the LHS we compared the value
of the parameter in that set to the base value as well as the final prevalence of that set
compared to the base final prevalence (what the model predicted when
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Table 1. Baseline parameter values

all parameters were at base values). By comparing the ratios between these two numbers we
could estimate how much variation any one parameter contributed to the final prevalence. By
averaging all these values for a given parameter we could get an estimate for how much
influence that parameter had on the final prevalence over the entire sensitivity analysis.
Parameters that have higher ARI values would indicate that small changes in that parameter’s
value led to large changes in final prevalence.

Predicting Treatment Efficacy
After identifying these prevalence-sensitive parameters, we compared the null model
to the sex-structured one using several sample scenarios inspired by prior research. These
three scenarios were: (1) a population made up of 70% males and 30% females (Unpublished
U-Find-Out Cohort Data), (2) a population where women clear 40% of new infections while
men clear only 15% (Micallef et al., 2006; Wang et al., 2007), and (3) a population where
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women are 25% more susceptible to new infections compared to men (Esmaeili et al., 2017).
In the sex-structured model, the male population had one parameter value, while the female
population had another parameter value. In the null model, which does not differentiate
between sex, the parameters were averaged. The one exception was in the population ratio
scenario, where the null model does not differentiate between sex and susceptible and
chronic individuals were pooled. In any given scenario, only the parameters of interest were
changed, while others were held at base values (Table 1). Both models were then run under
each scenario with the maximum yearly treatments set to zero and scaled up incrementally to
determine the minimum number of treatments required to reduce prevalence of HCV by 90%
at the 30-year mark.
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Results
For the global sensitivity analysis, population ratio, male and female susceptibility,
and male and female spontaneous clearance all had significant linear relationships with final
prevalence of HCV, though the effect size varied between them (Figure 2). Male and female
susceptibility had the strongest positive effect, with higher susceptibility leading to a higher
final prevalence regardless of other factors (Male – ARI: 0.55, p < 0.001; Female – ARI:
0.59, p < 0.001, Figure 2a, b).

Figure 2. Results of global sensitivity analysis without treatment. Trend lines are fit using local regression to capture
relationship between parameters of interest (a) male susceptibility, (b) female susceptibility, (c) male spontaneous clearance,
(d) female spontaneous clearance and final chronic prevalence of HCV. Final prevalence is reported as a proportion of the
population after a time period of 30 years. Shaded regions correspond to 90% confidence intervals.
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Population ratio had the strongest individual effect on final prevalence (ARI: 0.86) with
small changes in highly male or female dominated populations leading to large changes in
final prevalence, while only having small changes in balanced populations. (Figure 3a).
While male and female clearance both had a significant

Figure 3. Kernel density estimation of 10,000 samples of population ratio against final prevalence of HCV for the (a)
untreated and (b) treated scenarios. Lower population ratio corresponds to a primarily female population, and higher ratio
corresponds to a primarily male population. Final prevalence is reported as a proportion of the population after a time period
of 30 years. Linear model estimation is denoted by the dashed line.

negative correlation with final prevalence, the effect size was relatively small in comparison
to susceptibility (Male – ARI: 0.06, p < 0.001, Female – ARI: 0.28, p < 0.001, Figure 2c, d).
When susceptibility was restricted relative to one sex, a much stronger population ratio effect
appeared, which depended on which sex had the lower susceptibility (Figure 4a). In the case
of low female susceptibility, the population ratio had a positive effect on final prevalence (p
< 0.001) while a negative effect was seen when males had low susceptibility (p < 0.001). The
effect of clearance rates heavily depended on which sex had a lower relative susceptibility.
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Figure 4. Results of global sensitivity analysis without treatment and with low female susceptibility. Linear model estimates
are shown between (a) population ratio, (b) male clearance, (c) female clearance and final chronic prevalence of HCV. Final
prevalence is reported as a proportion of the population after a time period of 30 years. Female susceptibility has been
restricted to 0.2-0.3 and male susceptibility is at baseline value of 0.4. Shaded regions correspond to 90% confidence
intervals.

When females had low susceptibility relative to males, female clearance had a significant
negative relationship with final prevalence (p < 0.001, Figure 4c), whereas male clearance
rate did not have a noticeable effect on final prevalence (p = 0.23, Figure 4b). In the case of
low male susceptibility, this trend was reversed with male clearance having a slight negative
effect on final prevalence (p = 0.007) while female clearance did not have a noticeable effect
(p = 0.19).
In the treated populations, the sensitivity analysis showed that all five parameters
maintained significant relationships with final prevalence (Figure 3b, Figure 5). In the case
of susceptibility there was again a strong positive effect for both males and females on final
prevalence (both p values < 0.001, Figure 5a, b). The effect for the population ratio and
clearance rates was less clear. Population ratio had a strong negative effect that resulted from
a cluster of female dominated populations where final prevalence was much higher than in
other parameter sets (ARI: 1222.39, Figure 3b). Such a high ARI indicates high variance in
the parameter
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Figure 5. Results of global sensitivity analysis with treatment. Trend lines are fit using local regression to capture the
relationship between (a) male susceptibility, (b) female susceptibility, (c) male spontaneous clearance, (d) female
spontaneous clearance and final chronic prevalence of HCV. Final prevalence is reported as a proportion of the population
after a time period of 30 years. Treatment is applied at a constant rate over the time period. Shaded regions correspond with
90% confidence intervals.

which is matched in the male clearance rate for treated populations (ARI: 3649.11). Both
ARI values were considerably higher than in the untreated simulations indicating that small
changes in these parameter values resulted in large changes in final prevalence. The rest of
the parameters were more comparable to the untreated analysis, although ARI’s were higher
indicating an overall greater variance. When susceptibility was restricted once again,
population ratio kept a strong relationship such that populations predominantly made up of
the low susceptibility sex had lower final prevalence (p < 0.001). In the cases with low
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female susceptibility, both male and female clearance had significant negative impacts on
final prevalence unlike the untreated scenario (p = 0.003 and 0.001 respectively). During
scenarios of low male susceptibility though, male spontaneous clearance did not have a
significant impact on final prevalence while female spontaneous clearance still did (p = 0.791
and 0.006 respectively).
For the treatment efficacy comparison, when the null model was compared to the sexstructured model, as expected, there was no difference in treatments required when all
parameters were at baseline (Table 1). In the high male population ratio scenario, both the
sex-structured and null model required a minimum of 29.96 treatments/1000 person years to
reduce prevalence by 90% at the 30-year mark. When treatment was applied opposite the
bias, such as when females who only made up 30% of the population received 50% of the
available treatments, the sex-structured model required a much lower minimum number of
treatments to get the same reduction in prevalence (5.68 treatments/1000 person years,
Figure 6a). Additionally, if given the minimum treatment rate of 29.96 from the null model,
the sex-structured model showed quicker reductions in prevalence (S.I. Figure 2a). When
treatment was allocated according to the bias present in the population both models required
similar minimum treatment amounts but when treatment was distributed more equally the
sex-structured model required less treatments to achieve the same goal. For the higher female
clearance scenario, the sex-structured model required approximately 10 less treatments per
1000 person years (Null: 28.52 treatments/1000 person years Sex-structured: 15.78
treatments/1000 person years, Figure 6b). In addition, when the sex-structured model was
run with the minimum treatments from the null model, it showed quicker reductions in
prevalence (S.I. Figure 2b). Finally, in the higher female susceptibility scenario, the sex-
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structured model required approximately 2 fewer treatments per 1000 person years (Null:
40.10 treatments/1000 person years Sex-structured: 38.16 treatments/1000 person years,
Figure 6c). This scenario also showed quicker reductions in prevalence when the sexstructured model was run with the minimum treatments from the null model (S.I. Figure 2c).
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Figure 6. Chronic Prevalence over 30 years given minimum treatment required to reduce prevalence by 90% for three
specific scenarios: (a) 70% male to 30% female population ratio, (b) 15% male spontaneous clearance to 40% female
spontaneous clearance, and (c) female susceptibility is 25% higher than males. Male and Female lines are from sexstructured model, while null line is from null model.
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Discussion
Even with the development of effective treatment methods, we have still been unable
to curb the rapid transmission of HCV across the globe. Our work builds on prior research
through the use of sex-structured populations. This allows us to explore model dynamics by
varying per-sex transmission, spontaneous clearance, and treatment rates. The results from
these additional dynamics may lead to further refinement of intervention methods. Prior
modeling work has either ignored or glossed over these differences for convenience (Cousien
et al., 2015; Fraser et al., 2018a; 2018b; Gountas et al., 2017; Li et al., 2015; Martin et al.,
2011a; 2011b; 2013a; 2013b; Vickerman et al., 2012). Not only does this allow us to
investigate any sex-specific outcomes but given the case where there is no difference our
model still displays the same dynamics as a null model.
Investigating the impact of sex differences on final prevalence highlights several key
results. First, the strongest influence on final prevalence is how susceptible a population, or
one sex, is to new infections (Figure 2a,b; Figure 5a,b). While the research on how much
genetics influences HCV susceptibility is inconclusive (Cai et al., 2014; Esmaeili et al., 2017;
2018; Iversen et al., 2015; Tracy et al., 2014, Mekky and Abdelaziz, 2013), it is important
when discussing interventions such as opioid substitution or needle exchange programs.
These programs can be considered a type of susceptibility reduction because of suppressing
high risk behaviors that contribute to HCV transmission (Amato et al., 2005; Edlin and
Winkelstein, 2014; Lawrinson et al., 2008; Platt et al., 2018). We also found that population
ratio demonstrated a high variance at the extremes which demonstrates that populations of
mostly men or mostly women can have severely different disease burdens compared to each
other (Figure 3a). If we relied solely on a linear model to determine if a given parameter had
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a significant relationship with prevalence, some of this variation would be lost. As we were
explicitly testing parameters that had an impact on one sex over another, these could lead to
heavy transmission bias within the population. When a population consists of a high
proportion of one sex, it naturally amplifies any resilience or susceptibility that sex has to
infection. In a way, when one sex has high susceptibility and low clearance, a population
dominated by that sex naturally trends to higher final prevalence, an “amplification” of their
vulnerability. If one sex has low susceptibility and high clearance rates, the opposite will
occur. Therefore, we calculated the ARI for each of our parameters as well as estimating the
linear relationship between parameter and model outcome. A parameter with a high ARI
indicates that either the parameter had a strong linear effect on the final prevalence or that
there was a strong interaction with other parameters near the extremes.
While susceptibility has the clearest association with final prevalence in untreated
populations, after its effect has been controlled for, there is a strong population ratio effect
(Figure 4a). This is important considering that the population of PWID is often not reflective
of the 50/50 sex ratio in the general population. Other literature finds that recruitment rates
vary between male and female individuals which could lead to this population disparity
(Ahamad et al., 2014; Doherty et al., 2000). We also see that when one sex had low
susceptibility to new infections, spontaneous clearance becomes increasingly important to
reducing final prevalence (Figure 4b,c). The only exception to this was when male
susceptibility was low and yet male spontaneous clearance did not seem to significantly
decrease final prevalence. This likely results from the narrower range of values for male
spontaneous clearance compared to females (minimum 0.1 vs 0.2, maximum 0.3 vs 0.4). We
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also observed an overall smaller effect size of male clearance than female clearance in all our
tests which might result from the same bias.
When we perform the same analyses on a treated population the results are similar.
While susceptibility is still the strongest relationship (Figure 5a,b), once it has been
controlled for (depending on what level of susceptibility it was controlled at) there is also a
strong population ratio effect. Additionally, while we still see a significant female clearance
effect, we also see a significant male clearance effect (Figure 5c,d). This results from the
fact that in our treated analysis the treatments applied each year were at a level to keep
overall prevalence low. Thus, each spontaneous clearance event, whether male or female,
was that much more impactful on reducing transmission and overall final prevalence.
Unique to the treatment sensitivity analysis, we saw a much higher level of variance
for all five parameters indicated by the higher average ARIs. Like the untreated scenario,
there was a strong polarizing effect of population ratio on final prevalence (Figure 3b).
When populations were biased towards females we saw more “escape scenarios” where the
final prevalence ended much higher than most other samples. When populations were biased
towards males, we saw a similar number of “escape scenarios” yet these never reached the
prevalence levels of the female biased populations. While these results are infrequent in
comparison to the simulations with low final prevalence, they do pose an interesting question
of how this difference occurs. When looking at the total samples for male and female
susceptibility in treated scenarios we see a slight difference in their spread. Across the range
of female susceptibility, prevalence seems to be low without a high level of female
susceptibility while males can reach high prevalence at any level of susceptibility (S.I.
Figure 1). This could be indicative of some type of threshold value in the female population,
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below which transmission cannot proceed normally. As we only saw this threshold for
female susceptibility under treatment regimes, focusing efforts on reducing female
susceptibility might be the best option for populations with high levels of treatment already.
Each of our sample scenarios to compare treatment requirements were designed as
hypothetical situations representing populations described in the literature. As some studies
have reported differences in recruitment rates between males and females into the PWID
population, it would be important to consider how a highly polarized sex ratio might impact
interventions (Evans et al., 2003; 2012; Tracy et al., 2014). Additionally, there is a significant
amount of evidence implying a higher level of clearance in women compared to the average
value attributed to both sexes in previous modeling work (Bakr et al., 2006; Fedorchenko et
al., 2010; Grebely et al., 2007; Micallef et al., 2006; Wang et al., 2007). Finally, while the
question of susceptibility is still under investigation, there have been some studies that
indicate a bias between the sexes (Esmaeili et al., 2017; 2018). The results of our three
scenarios and how they might inform intervention methods for these unique populations is
one of the major applications of a sex-structured model.
When we look at our sample scenarios, the sex-structured model shows higher
treatment efficacy compared to the null model (Figure 6). A key finding of this is that the
higher efficiency arises after applying treatment against the bias already present in the
population. In the high male population scenario, the simulation modeled a population that
was 70% male and 30% female and applied 70% of treatments to men and 30% to women.
When this was the case, both models functioned very similarly. It was not until treatments
were applied more equally (50% to men, 50% to women) that the reduction in minimum
treatments was observed (Figure 6a). In other words, preferring to treat women even though
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they make up a smaller part of the population led to a more efficient treatment regime. The
same effect occurs for the other two scenarios; when females show increased susceptibility it
might make sense to appropriate more treatments to them, but instead the more efficient
method was to again apply treatments equally as was the case in the higher clearance
scenario as well (Figure 6b). That is not to say that applying treatments opposite any bias
present is the absolute best method. In all three scenarios, the lower level of initial treatments
in the sex-structured model did lead to transient dynamics wherein the prevalence increased
for a short period of time before transmission was controlled and reductions started to show,
while the null model displayed immediate reductions in prevalence.
Given no monetary or logistic issues with larger numbers of treatments, the sexstructured model does predict a quicker time to reduce prevalence when compared to the null
at any given number of treatments above the minimum (S.I. Figure 2). Thus, using the null
model may overestimate the number of treatments required or underestimate the time to
observe prevalence reductions in a population. Furthermore, while the sex-structured model
does predict a lower minimum number of treatments, it does not automatically imply it is
better. Depending on the circumstances within the population, it might be more important to
be conservative, in which case the null model works well, or it might be more important to be
strategic and efficient, in which case the sex-structured model allows for that. The key
outcome of this research is the importance of considering the demographics and context in
which the intervention is being applied.
There are several limitations to our study. Some assumptions about the transmission
dynamics are made to simplify the model and thus might be unrealistic. Notably, assuming
all infectious classes equally contribute to the force of infection (especially those on
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treatment) most likely overestimates the force of infection. Also, we did not assume any type
of age, social, or risk structure. It is well reported that individuals often inject with sexual
partners or within social groups and that some are more likely to engage in risky behavior
such as sharing needles, which would lead to some individuals in the population transmitting
or receiving more infections proportionally (Morris et al., 2015; 2017; 2018; Tracy et al.,
2014). Including this structure in future work will allow us to examine how sex might
interact with these other factors to change HCV transmission. We also assumed that our
initial populations had no individuals with an acute infection, as it is hard to find data on
newly acquired HCV infections (Shepard et al., 2005). Since the duration of acute infection
is relatively short compared to the time span of our simulations, this was assumed to have a
negligible effect on final prevalence but would merit exploration as well. We also capped the
proportion of our population accessible by treatment at 50%. This assumption was a
conservative one as it is unlikely that any population will be able to access and treat their
entire infected PWID population, but some may be able to reach higher proportions than
what we set. In the sensitivity analysis, we sampled all parameters from a uniform
distribution across their given range, but it is more likely that their values tend to fall in the
center of the range rather than at the extremes. While we restricted our parameter ranges to
avoid some of these extremes, we did not have any strong evidence to predict the actual
distribution across the ranges we used. Future research that expands upon this would be
useful for exploring the unusual differences between male or female biased populations in
treated scenarios.
As a burgeoning global epidemic and a major public health issue HCV is a problem
waiting to be solved. We have the tools at our disposal, now it is time to figure out how to
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use them. The work presented here provides insight into how a few key sex-structured
parameters can lead to large changes in treatment efficacy and overall transmission
dynamics. Notably, it shows how understanding the population of interest and any bias that
might be present is critical for determining the method of treatment application. Once that
context is understood, it will not only lead to better intervention methods in the present, but
also allow for more thorough evaluations of interventions going forward.
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Supplemental Figures

Supplemental Figure 1. Kernel density estimation of 10,000 samples with (a) male and (b) female susceptibility versus
final HCV prevalence with treatment. Final prevalence is reported as a proportion of the population after a time period of 30
years. Linear model estimation is denoted by the dashed line.
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Supplemental Figure 2. Chronic Prevalence over 30 years for three specific scenarios: (a) 70% male to 30% female
population ratio, (b) 15% male spontaneous clearance to 40% female spontaneous clearance, and (c) female susceptibility is
25% higher than males. Male and Female lines are from sex-structured model, while null line is from null model. Both
models run with the same number of yearly treatments, as determined by minimum number required to reduce prevalence by
90% at the 30 year mark for the null model.
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